Coloplast completes the acquisition of Kerecis
Coloplast has completed the acquisition of Kerecis, announced on July 7, 2023, after receiving approval from all relevant authorities and reaching a shareholder acceptance level of 100%
The terms of the transaction and the financial assumptions stated in Coloplast's stock exchange announcement no. 03/2023 regarding the acquisition of Kerecis are unchanged. The equity capital raise related to the financing of the acquisition was completed on August 30, 2023.
Kerecis will be included in the financials for FY 2022/23 with 1 month of impact. Revenue contribution will be included as acquired growth under the existing Wound and Skin Care business area, which will be renamed to Advanced Wound Care. The financial guidance for FY 2022/23 as described in the Interim Financial Report for 9M 2022/23 (announcement no. 04/2023) is unchanged.
Kerecis – an emerging category leader in the US-centric biologics wound care segment
Kerecis is an innovative, fast-growing company in the biologics wound care segment with a strong commercial presence in the US. The company has developed and patented a clinically differentiated technology based on intact fish skin. The fish-skin technology is minimally processed, sustainable, and scalable. Backed by compelling clinical evidence, the technology has already been used to treat tens of thousands of patients.
With the acquisition of Kerecis, Coloplast obtains a long-term growth business with strong profitability expansion potential, well-positioned for long-term value creation.
“I am very excited to welcome the Kerecis team into the Coloplast family. Both Coloplast and Kerecis are on a mission to help many more patients in need of advanced wound treatment, and I look forward to continuing the growth and profitability journey, as we build a truly global wound care franchise together” says Kristian Villumsen, President & CEO of Coloplast and continues: “On September 4, we will host a conference call where investors and analysts will get an opportunity to meet Fertram Sigurjonsson, founder and CEO of Kerecis. Fertram is an outstanding leader, and I am impressed by the strong results that he and his team have created. The success of Kerecis is a testament to both the strength of its unique fish-skin technology, as well as strong commercial execution, enabled by a highly motivated and purpose-driven organisation” says Kristian.
“We look forward to continuing our strong growth trajectory as part of Coloplast. Kerecis can leverage Coloplast’s expertise, capabilities, and industry-leading infrastructure to secure the long-term success of our company and become a category leader in the biologics segment. I would like to thank everyone at Kerecis for a fantastic journey so far, and I look forward to entering the next chapter together and reaching many more patients with our patented technology based on intact fish skin” says Fertram Sigurjonsson, founder and CEO of Kerecis, who will continue to lead the Kerecis team.
As a result of the agreement to acquire Kerecis, Coloplast raised its long-term organic growth guidance to 8-10%, from previously 7-9%, on July 7, 2023. The long-term EBIT margin guidance was maintained at above 30% beyond FY 2024/25. The EBIT margin is expected to remain below 30% in the Strive25 strategic period and includes around 100 basis points dilution p.a. from Kerecis (incl. PPA amortisation). Kerecis has an attractive gross margin level, accretive to Coloplast’s gross margin, and thus strong potential to expand its profitability driven by continued growth and scalability. The transaction is expected to be increasingly EPS accretive from FY 2026/27.
For further details on the acquisition of Kerecis, please refer to stock exchange announcement no. 03/2023 from July 7, 2023 (Coloplast announces agreement to acquire Kerecis). For more information on the completion of the equity capital raise related to the financing of the acquisition, please refer to stock exchange announcement no. 07/2023 from August 30, 2023 (Equity Issue of B Shares (coloplast.com)). For details on the financial guidance for FY 2022/23, please refer to announcement no. 04/2023, Interim Financial Report for 9M 2022/23 (9M 22/23 Earnings Release (coloplast.com)).
Investor and analyst conference call with Fertram Sigurjonsson, founder and CEO of Kerecis
Coloplast will host a conference call on September 4, 2023, at 14.00h CEST. On the call, Kristian Villumsen, CEO and President, and Anders Lonning-Skovgaard, CFO and EVP, will be joined by Fertram Sigurjonsson, founder and CEO of Kerecis.
Access the conference call webcast directly here: Coloplast conference call (getvisualtv.net)
To actively participate in the Q&A session, please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Diamond Pass Registration (choruscall.it)
For further information, please contact
Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111
Aleksandra Dimovska
Senior Director, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: [email protected]
Kristine Husted Munk
Senior Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 3266
Email: [email protected]
Press and media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: [email protected]
Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917
Website
www.coloplast.com
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.
This announcement includes forward-looking statements that involve risks, uncertainties, and other factors, many of which are outside of Coloplast's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Coloplast's plans, objectives, goals, future events, performance, and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Coloplast undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology and Voice and Respiratory Care. We operate globally and employ more than 14,700 employees.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2023-08.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.
Attachment
